Xoma reported $-17.24M in Net Income for its fiscal quarter ending in September of 2024.





Net Income Change Date
AbbVie USD 695M 1.12B Mar/2026
Agenus USD -10.63M 74.49M Dec/2025
Agios Pharmaceuticals USD -99.11M 8.93M Mar/2026
Ardelyx USD -407K 562K Dec/2025
aTyr Pharma USD 24.56M 50.3M Dec/2025
BioMarin Pharmaceutical USD 105.53M 152.1M Mar/2026
Celldex Therapeutics USD -81.32M 14.27M Dec/2025
Curis USD 19.36M 31.16M Dec/2025
Eli Lilly USD 7.4B 760M Mar/2026
Emergent BioSolutions USD -261.3M 78.3M Jun/2023
Incyte USD 303.33M 4.05M Mar/2026
MacroGenics USD -14.16M 30.98M Dec/2025
Novartis USD 3.16B 747M Mar/2026
Novartis USD 2.41B 1.52B Dec/2025
Pfizer USD -1.65B 5.19B Dec/2025
Prothena USD -21.59M 14.95M Dec/2025
Regeneron Pharmaceuticals USD 727.2M 117.4M Mar/2026
Xoma USD -17.24M 33.23M Sep/2024